What is the Aromasin dosage for men?
| Label item | What it says |
|---|---|
| Tablet strength | 25 mg tablets1 |
| Pack | Bottles of 30 tablets1 |
| Schedule | One 25 mg tablet once daily after a meal, by mouth, in early and advanced breast cancer1 |
| Early breast cancer course | Five consecutive years of adjuvant hormonal therapy in total, after two to three years of tamoxifen1 |
Aromasin strength and labelled schedule
The table is set at the top of the page
The label's only dose change is 50 mg once daily after a meal with a strong CYP 3A4 inducer such as rifampicin or phenytoin.1 It gives no stepped or titrated schedule.1 The only labelled form found is a tablet, so there is nothing to mix and no syringe mark.
Is Aromasin labelled for men, TRT or cycles?
The label's indication is postmenopausal women with breast cancer.1 A search found no label indication and no registered trial for men on TRT or steroid cycles. It also found no label or human trial giving a dose for bodybuilding, TRT, cycles or post-cycle therapy.
A qualitative analysis by Blazewicz and colleagues (2025) of 63 samples meant for unapproved post-cycle therapy, seized from the illegal market and tested at the Polish Official Medicines Control Laboratory, found 25.4% labelled as aromatase inhibitors (anastrozole, letrozole and exemestane together); the paper reports the declared ingredient present in 65.1% of the samples and absent in 34.9%.3 The WADA 2026 Prohibited List names exemestane among aromatase inhibitors (S4.1), prohibited at all times, in and out of competition.4
What the trials in men used
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Mauras 2003 | 25 mg and 50 mg daily, orally, in a randomised cross-over2 | 12 healthy eugonadal males aged 14 to 262 | 10 d each, 14-d washout2 |
| MALE (NCT01638247) | 25 mg exemestane daily with goserelin 10.8 mg or leuprorelin 11.25 mg s.c. after randomisation and after three months, against tamoxifen with or without a GnRH analogue5 | 56 men with breast cancer enrolled5 | Treatment length not in the saved entry; outcomes after three and six months5 |
| Bonomo 2003 (Swiss Group) | Not available6 | Men with prostate carcinoma; size not in the saved record6 | Not available |
In Mauras 2003 (12 healthy eugonadal males aged 14 to 26), plasma estradiol measured 24 h after the last dose fell 38% on 25 mg and 32% on 50 mg, which the authors call comparable, while testosterone rose 60% and 56%; the authors add that long-term efficacy and safety will need further study.2 The Swiss Group record (Bonomo 2003) is titled as reporting that exemestane seems to stimulate tumour growth in men with prostate carcinoma.6 Its saved record has no summary text, so no dose or size is available.6
How Aromasin tablets are stored
The label says to store the bottle at 25°C (77°F), with excursions permitted to 15°–30°C.1 Its patient information gives room temperature, 68°F to 77°F (20°C to 25°C).1
Frequently asked questions
Does the label say to take Aromasin with food?
The label says one tablet once daily after a meal.1
Does the label adjust the dose for liver problems?
The label says the AUC of exemestane was increased in subjects with moderate or severe hepatic impairment (Childs-Pugh B or C), but that dosage adjustment does not appear to be necessary, based on experience with repeated doses up to 200 mg daily that demonstrated a moderate increase in non life-threatening adverse reactions.1
Does the label say anything about fertility in men?
The label says male and female fertility may be impaired, based on animal findings.1
References
- Pfizer (Pharmacia & Upjohn), DailyMed. These highlights do not include all the information needed to use AROMASIN safely and effectively. See full prescribing information for AROMASIN. AROMASIN® (exemestane) tablets, for oral use Initial U.S. Approval: 1999. 2025. dailymed.nlm.nih.gov
- PubMed. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. 2003. pubmed.ncbi.nlm.nih.gov
- PubMed. Illegal and falsified medicines self-administrated in not approved post-cycle therapy after the cessation of anabolic-androgenic steroids - qualitative analysis. 2025. pubmed.ncbi.nlm.nih.gov
- WADA. WORLD ANTI-DOPING CODE. wada-ama.org
- ClinicalTrials.gov. NCT01638247: Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients. 2018. clinicaltrials.gov
- PubMed. Exemestane seems to stimulate tumour growth in men with prostate carcinoma. 2003. pubmed.ncbi.nlm.nih.gov